Abstract: Ovarian cancer is one of the three malignant tumors of the female reproductive system and also one of the main causes of death related to gynecological malignancies. Although treatment regimens including surgery and chemotherapy, have shown some success, the 5-year overall survival rate of patients with ovarian cancer is still unsatisfactory. One reason is that most ovarian cancers are asymptomatic in the early stages and diagnosed late. The other is due to the increased recurrence rate and resistance to chemotherapy. The key to reducing mortality in patients with ovarian cancer is early diagnosis and treatment and effective prediction of chemotherapy resistance. Studying the expression patterns of genes and proteins associated with ovarian cancer is critical to promoting the production of diagnostic biomarkers and to providing new research targets for drug design, treatment and resistance. In recent years, long non-coding RNA (lncRNA) plays an increasingly important role. Abnormal expression of lncRNA has been found in many diseases, including cancer, but its exact role in the etiology and biology remains unclear. With the further study on the mechanism of ovarian cancer, it has been reported that abnormal expression of lncRNA is related to platinum/paclitaxel resistance. This paper reviewed the recent advances in the application of lncRNA in chemotherapy resistance of ovarian cancer.

Key words: Ovarian neoplasms；, RNA, long noncoding；, Drug resistance, neoplasm；, DNA damage；, Apoptosis；, Autophagy